Sanofi files lawsuit against Novo Nordisk over ‘false allegations’
January 3, 2017Manufacturing and Production, Sales and Marketing Novo Nordisk, Sanofi
Sanofi has sued Novo Nordisk over claims made in an advertising campaign for its drug Tresiba. Sanofi has filed the …
Sanofi and Boehringer confirm successful exchange of businesses
January 3, 2017Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, Sanofi
Sanofi and Boehringer Ingelheim have confirmed the successful completion of the exchange of Sanofi’s animal health business (Merial, based in …
Mylan ends 2016 with spate of generics
January 3, 2017Manufacturing and Production, Sales and Marketing Mylan, generics, launch
Mylan ended a difficult year for itself by releasing a rash of generics into the market, ending the year strongly …
Pfizer announces acquisition of small-molecule business from AZ for $550 million
December 23, 2016Medical Communications AstraZeneca, Pfizer
Pfizer has announced that they have acquired AstraZeneca’s small molecule anti-infectives business for an upfront fee of $550 million. Pfizer …
French clinical trial tragedy did not check all data
December 23, 2016Medical Communications Bial
There have been new revelations regarding the fatal French clinical trial that occurred in January of this year. Nature reports …
Teva hit with record fine $519 million corruption fine
December 23, 2016Medical Communications Teva, corruption, fine
Teva Pharmaceuticals, the world’s largest generics company, has been hit with the largest criminal fine to come from the US …
2016 Top markets report
December 23, 2016Medical Communications market, market access
2016 Top Markets Report
Top Ten most popular articles on Pharmafile.com this year
December 23, 2016Medical Communications biggest news, biggest stories, top 10, top 10 stories, top stories, top ten
As we’re now in the New Year, here at Pharmafocus, we thought we would do a recap of the ten …
Merrimack’s breast cancer trial stutters to halt
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merrimack Pharmaceuticals, merrimack
Merrimack Pharmaceuticals announced that it had decided to stop a Phase 2 study of MM-302, a HER2 antibody-targeted liposomal doxorubicin, …
Impax Laboratories parts with CEO
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Impax Laboratories
Impax Laboratories announced on 20 December that CEO Frederik Wilkinson has left his position of president and CEO, as well …
Seven pharma trends for 2017
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing M&A, MA, biosimilars, collaborations, digital pharma, emerging markets, patient centricity, pharma, pricing
What will be the key industry trends in 2017?Industry uncertaintyPerhaps the biggest hallmark of 2016-going-into-2017 is the sense of hesitation …
Fluor wins $2 billion Novo contract to build API manufacturing facility
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Fluor, Novo Nordisk, north carolina
Fluor Corporation has won an engineering, procurement and construction management contract for Novo Nordisk’s $2 billion diabetes active pharmaceutical ingredient …
Actelion acquisition hokey-cokey continues with J&J returning to table
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, Johnson & Johnson, Sanofi
The Actelion takeover saga continues with Johnson & Johnson back in the game, and now re-entering into exclusive negotiations. Actelion …
Sun Pharma to acquire Novartis’s drug for $175 million
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Sun Pharma
Sun Pharma has announced that it will acquire Odomzo from Novartis for an upfront fee of $175 million alongside additional …
Roche’s ground-breaking MS drug delayed by manufacturing issues
December 22, 2016Genentech, MS, Roche, multiple sclerosis
Roche has released both good and bad news just before Christmas. The good news is very good news for individuals …
Colombian government forces through near half-price cut of Novartis drug
December 21, 2016Medical Communications, Sales and Marketing Colombia, Novartis
The Colombian government has lowered the price of Glivec (imatinib) by 44%, a cancer drug made by Novartis. The case …
New research reverses HIV-related immune suppression
December 21, 2016Research and Development HIV, UNC School of Medicine
The UNC School of Medicine has released new research which appears to offer a new approach to HIV treatment which …
FDA new drug approvals sink to six year low
December 21, 2016Medical Communications, Research and Development FDA, NDA, new drug approvals
The FDA has released figures to show that drug approvals have fallen from last year’s high of 45 new drugs …
Allergan shells out $2.9bn for regenerative medicine unit LifeCell
December 21, 2016Research and Development, Sales and Marketing Allergan, LifeCell, acquisition
Allergan has agreed a deal to acquire Acelity-owned regenerative medicine unit LifeCell for $2.9 billion in cash, assimilating its portfolio …
Novartis seals two deals to bolster drug pipeline
December 21, 2016Research and Development Conatus, Encore Vision, Novartis
Novartis has consolidated its ophthalmology position by acquiring Encore Vision, a Fort Worth-based US company. The company is focused on …
